eligibility_summary
Eligibility: Advanced/metastatic ovarian, ESCC, TNBC, NSCLC, SCLC, HNSCC, gastric/GEJ adenocarcinoma, cervical SCC, or endometrial cancer, prior SOC or none, tumor tissue, measurable disease (RECIST v1.1), ECOG 0–1, adequate organs. Exclude: prior PTK7 (and TOP1 ADC in Ph1b), Ph1b: neuroendocrine or endometrial sarcoma, ovarian platinum-sensitive or primary platinum-refractory, nasopharyngeal primary, recent SBO, frequent ascites, active brain/lepto, >G1 toxicities, systemic therapy within 5 half-lives or 4 wk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: DAY301, a PTK7-targeted antibody–drug conjugate (ADC) given intravenously. Mechanism: the monoclonal antibody binds the cell-surface receptor PTK7 (protein tyrosine kinase 7), is internalized, and releases a conjugated cytotoxic payload inside tumor cells to induce cell death. PTK7 is a catalytically inactive receptor (pseudokinase) implicated in Wnt/planar cell polarity signaling, cell migration, and proliferation, and is overexpressed across many solid tumors. Targets/pathways: PTK7-expressing tumor cells and the PTK7/Wnt-PCP axis. Tumors: ovarian, esophageal SCC, TNBC, NSCLC, SCLC, HNSCC, gastric/GEJ adenocarcinoma, cervical SCC, endometrial. Phase 1 dose escalation/expansion to define MTD/RD and assess safety, PK, and antitumor activity.